ResMed (RMD) PT Raised to $280 at KeyBanc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $241.35 +6.28%
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
KeyBanc analyst Matthew Mishan raised the price target on ResMed (NYSE: RMD) to $280.00 (from $276.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fortune Brands (FBIN) PT Lowered to $58 at DA Davidson
- Contineum Therapeutics (CTNM) PT Lowered to $23 at Stifel
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
